Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma

Exclusion criteria

• ✕. Allergy or hypersensitivity to brimonidine or other components of brimonidine tartrate 0.025% or netarsudil 0.02%/latanoprost 0.005%.
• ✕. Use of any other topical ocular medications.
• ✕. Active ocular infection, inflammation unrelated to glaucoma therapy, uveitis, iritis or congenital aphakia.
• ✕. Have pterygium/pinguecula, chemosis, episcleritis, scleritis (or any condition that may affect hyperemia grading) in the opinion of the investigator
• ✕. Have moderate or severe dry eyes.
• ✕. Pregnant, plan to become pregnant or breastfeeding.
• ✕. Concurrent or past use in the last 90 days of vasoconstrictive ocular drops other than brimondine 0.025%
• ✕. Have undergone previous incision IOP lowering surgeries.